FindTrial
Sign In

Application Research of CD3 Bright T Cells in Long-term prognosis Evaluation of Hepatocellular Carcinoma

Application Research of CD3 Bright T Cells in Long-term prognosis Evaluation of Hepatocellular Carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900024791
Enrollment
Unknown
Registered
2019-07-27
Start date
2019-07-30
Completion date
Unknown
Last updated
2019-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis carcinoma

Interventions

Gold Standard:pathologic diagnosis
AFP
Index test:CD3 bright T cells

Sponsors

Beijing Youan Hospital,Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 75 years; 2. the patients diagnosed as HCC; 3. Going to be treated by surgical operation or interventional therapy.

Exclusion criteria

Exclusion criteria: (1) preoperative child-pugh grade C; (2) preoperative evidence showed severe infection, such as laboratory examination of white blood cells, calcium calcitonin and other elevated; (3) receive liver transplantation treatment; (4) combined with thyroid diseases, autoimmune diseases and immunodeficiency related diseases; (5) with other organs dysfunction or malignant tumors; (6) Pregnant or lactating women; (7) Severe mental illness; (8) Intravenous drug users; (9) not Chinese resident; (10) accepted immunization or related treatment

Design outcomes

Primary

MeasureTime frame
recurrence of HCC;—

Countries

China

Contacts

Public ContactLiu Ning

Beijing Youan Hospital, Capital Medical University

liuning@ccmu.edu.cn+86 010-83997308

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026